Akebia Therapeutics Inc (AKBA) is near the middle in its industry group according to InvestorsObserver. AKBA gets an overall rating of 44. That means it scores higher than 44 percent of stocks. Akebia Therapeutics Inc gets a 63 rank in the Biotechnology industry. Biotechnology is number 93 out of 148 industries.
What do These Ratings Mean?
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 44 would rank higher than 44 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.
What's Happening With Akebia Therapeutics Inc Stock Today?
Akebia Therapeutics Inc (AKBA) stock has fallen -2.94% while the S&P 500 is higher by 0.14% as of 10:46 AM on Friday, Apr 16. AKBA is lower by -$0.09 from the previous closing price of $3.06 on volume of 1,459,986 shares. Over the past year the S&P 500 has risen 49.17% while AKBA is lower by -57.87%. AKBA lost -$2.77 per share the over the last 12 months.
Click Here to get the full Stock Score Report on Akebia Therapeutics Inc (AKBA) Stock.
